Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer

Cancer Research

Volumn 62, Issue 17, 2002, Pages 5049-5057

  Kass, Erik S ^a   Greiner, John W ^b   Kantor, Judith A ^b   Tsang, Kwong Y ^b   Guadagni, Fiorella ^c   Chen, Zhong ^a   Clark, Bradly ^b   De Pascalis, Roberto ^b   Schlom, Jeffrey ^b   Van Waes, Carter ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; EPITOPE; HLA ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY COL 1; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER IMMUNOTHERAPY; CELL LYSATE; CONTROLLED STUDY; CROSS REACTION; CYTOLYSIS; DRUG TARGETING; FLUOROIMMUNOASSAY; GASTROINTESTINAL CARCINOMA; GENE EXPRESSION; GENE OVEREXPRESSION; HEAD CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; NECK CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HLA-A2 ANTIGEN; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036733777     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Cancer statistics, 1999
2. Cancer of the head and neck
3. A triad of costimulatory molecules synergize to amplify T-cell activation
4. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells
5. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen
6. Agonist peptide from a cytotoxic T lymphocyte epitope of human carcinoembryonic antigen stimulates production of Tcl-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide
7. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
8. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas
9. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule
10. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
11. Association between CEA-specific T cell responses (TCR) following treatment with Vaccinia-CEA (V) and Alvac-CEA (A) and survival in patients (Pts) with CEA-bearing cancers
12. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
13. Elevated plasma CEA during radiotherapy for glottic carcinoma of the larynx
14. CEA levels in head and neck cancer
15. The detection of squamous cell tumours of the head and neck using radio-labeled antibodies
16. Immunohistochemical demonstration of carcinoembryonic antigen (CEA) on tissue sections from squamous cell head and neck cancer and plasma CEA levels of the patients
17. Carcinoembryonic antigen and head and neck cancer
18. Radioimmunodetection of head and neck cancer. A review
19. Squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA) and tumour-associated trypsin inhibitor (TATI) for monitoring head and neck cancer
20. Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: Lack of correlation
21. NK susceptibility varies inversely with target cell class I HLA antigen expression
22. Mutations in the alpha 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide
23. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen
24. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
25. Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen
26. Nucleotide sequences of genes encoding heat-stable and heat-labile glyceraldehyde-3-phosphate dehydrogenases; amino acid sequence and protein thermostability
27. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction
28. Differential expression of carcinoembryonic antigen in early gastric adenocarcinomas versus benign gastric lesions defined by monoclonal antibodies reactive with restricted antigen epitopes
29. Evaluation of human carcinoembryonic-antigen (CEA)-transduced and nontransduced murine tumors as potential targets for anti-CEA therapies
30. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line
31. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
32. Standardization, specificity, and diagnostic sensitivity of four immunoassays for carcinoembryonic antigen
33. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine
34. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer
35. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen
36. Detection of bloodborne cells in colorectal cancer patients by nested RT-PCR for carcinoembryonic antigen-mRNA: Longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers
37. Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas
38. Immunotherapy of head and neck cancer
39. Immunogenic variants of a murine fibrosarcoma induced by mutagenesis: Requirement of viable cells for antigen-specific cross-protection
40. Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer
41. The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin alpha 6 beta 4
42. Multifactorial analysis of p53 alteration in human cancer: A review
43. Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma
44. The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion
45. Differential expression of the murine Ly-6A/E antigen homolog of human squamous cell carcinoma antigen E48 during malignant transformation and tumor progression of squamous cell carcinoma line Pam 212
46. Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells
47. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
48. Tumor immunology
49. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice by immunizing with a recombinant vaccinia-CEA virus
50. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules
51. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects
52. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant
53. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine
54. Carcinoembryonic antigen as a vaccine target
55. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. Recombinant poxvirus vaccines
56. T lymphocyte activation
57. Expression of costimulatory molecules B7-1 and B7-2 on human gastric carcinoma
58. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
59. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity
60. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous carcinoma